Fig. 2.

Systemic application of IL-25 has no effect on functional or histological outcome following SCI in mice. (a) Repeated i.p. administration of IL-25 has no significant effect on functional outcome when compared to those receiving PBS, as measured by the BMS, n = 7 mice/group. Sections were stained for GFAP and MBP to determine the (b) lesion size and (c) demyelinated area, respectively. Image analysis revealed no significant difference in (b) lesion size or (c) demyelinated area in animals treated systemically with IL-25, compared with the PBS control group. Quantification of (d) Iba-1⁺ and (e) GFAP⁺ cells after SCI using TissueQuest software revealed no significant difference in microglia/macrophages numbers or astrogliosis between animals receiving PBS or IL-25. (f) There was no significant difference in the number of CD4⁺ T cells present in spinal cord sections of IL-25-treated mice, compared with PBS-treated mice. Data represent mean ± SEM, n = 7 mice/group